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Abstract
Background: To standardize gene product descriptions, a formal vocabulary defined as the Gene
Ontology (GO) has been developed. GO terms have been categorized into biological processes,
molecular functions, and cellular components. However, there is no single representation that
integrates all the terms into one cohesive model. Furthermore, GO definitions have little
information explaining the underlying architecture that forms these terms, such as the dynamic and
static events occurring in a process. In contrast, object-oriented models have been developed to
show dynamic and static events. A portion of the TGF-beta signaling pathway, which is involved in
numerous cellular events including cancer, differentiation and development, was used to
demonstrate the feasibility of integrating the Gene Ontology into an object-oriented model.
Results: Using object-oriented models we have captured the static and dynamic events that occur
during a representative GO process, "transforming growth factor-beta (TGF-beta) receptor
complex assembly" (GO:0007181).
Conclusion: We demonstrate that the utility of GO terms can be enhanced by object-oriented
technology, and that the GO terms can be integrated into an object-oriented model by serving as
a basis for the generation of object functions and attributes.
Background
Complexity combined with an imprecise terminology has
hindered the understanding of biology. A formal and
structured vocabulary is now being developed to address
this imprecise biology terminology. This vocabulary or
Gene Ontology (GO) is being developed by the Gene
Ontology Consortium (GOC) [1] to standardize the
descriptions of gene products. Ontologies define the basic
terms and relations comprising the vocabulary of a topic
area, as well as the rules for combining terms and relations
to define extensions to the vocabulary [2]. Despite these
efforts, the mechanism of representing these terms lacks a
unifying architecture that can be applied to the annota-
tion of a gene product. However, computer science has
developed a well-defined process and methodology for
the development of software models. Adapting this proc-
ess and methodology can orchestrate the assembly of bio-
logical models with integrated gene ontologies. In doing
so, a standardized terminology and object-oriented
model is created that can facilitate communication
between biologists and computer scientists.
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The Gene Ontology project is a collaborative effort that
addresses the need for a controlled vocabulary that pro-
vides a consistent description of gene products in different
databases [1]. The GO collaborators are developing three
structured, controlled vocabularies that describe gene
products, which have been classified into molecular func-
tion, biological process, and cellular component
domains. GO terms are organized in structures called
directed acyclic graphs (DAGs), which differ from hierar-
chies in that a 'child' (more specialized term) can have
many 'parents' (less specialized terms). As part of these
graphs, each component is given a GOid (unique identi-
fier), and is associated with a GO definition. Collectively,
these agreed upon terms are being developed to help
explain various aspects of biology. When applied to a
gene, that gene is annotated with a concise description of
its molecular function, cellular location and associated
biological processes. However, the GOC never intended
to represent gene products or correlate ontological terms
with these gene products [1]. To address this need, a Gene
Ontology Annotation database [3] has been created to
associate the GO terms with their gene product counter-
parts. With sustained effort, the descriptions of these gene
products will ultimately be established. Still, much of the
current bioinformatics work regarding GO has focused on
constructing databases [4-7], applying it to other research
areas [8-22], and building tools to mine the GO database.
(For a description of some of these tools see [23].)
In addition, there has been an ongoing discussion regard-
ing the depth of information obtained from the Gene
Ontology [24]. It has been noted that there remains a
need for a unifying architecture that integrates all three
GO domains as part of a gene product's annotation. Fur-
thermore, to enhance the Gene Ontology and facilitate its
use as a cross-disciplinary tool, several additional issues
need to be addressed. First, relationships between the bio-
logical processes, molecular functions and cellular com-
ponents are not readily apparent [25-28]. Second, GO
terms lack details. For instance, when one looks at molec-
ular function there is no indication of what is inputted or
outputted. Finally, existing tools such as GO-DEV [29]
only contain software used for tool development and
information retrieval, not software modeled directly after
the three domains of the Gene Ontology. However, these
issues can be resolved by integrating the Gene Ontology
into an object-oriented system.
On a conceptual level, the Gene Ontology has features
that support an object-oriented architecture. Conse-
quently, the Gene Ontology can be applied and mapped
to the fundamental concepts that form the object-oriented
paradigm (i.e. class, object, inheritance, composition,
polymorphism, and encapsulation) (Table 1). Further-
more, in an object-oriented sense, biological process
terms are equivalent to high-level concepts. However, GO
biological process terms do not contain descriptive infor-
mation about the dynamics or static interactions defined
by the terms. By translating a biological process into an
object-oriented model the dynamic and static events
occurring within a process can be represented. Building a
static and dynamic model of a biological process requires
defining the components of the process as well as the
functions and attributes contained within these compo-
nents. These components are biological entities (bioenti-
ties) that may include individual gene products, whose
processes, functions and cellular components are cap-
tured in the Gene Ontology, or other higher-level entities
such as gene product complexes.
The functions of gene products are the jobs or abilities
that it has. In the GO terminology these are described in
the molecular function domain. These are analogous to
the operations that an object can perform in an object-ori-
ented paradigm. Attributes, which define key properties of
a component that when changed may alter the function of
that component, may be defined by the cellular compo-
nent and molecular function sections. For example, the
cellular component domain can specify the place in a cell
where a gene product is located. When there are multiple
cellular components associated with a gene product, how-
ever, there is currently no mechanism to designate which
cellular component represents the appropriate location.
The unified modeling language has been used to capture
various aspects of biology [30-32]. These examples high-
light the utility of the unified modeling language as a tool
for biological data integration, and indicate that it can be
applied to construct large, complex biological models.
Therefore, to demonstrate the feasibility of integrating the
Gene Ontology into an object-oriented model we have
created unified modeling language (UML) representa-
tions of a GO biological process, "transforming growth
factor beta (TGF-beta) receptor complex assembly"
(GO:0007181).
The TGF-beta receptor pathway is involved in numerous
cellular events including apoptosis, tumor development,
differentiation, and development. These processes stem
from the binding of TGF-beta to its cellular receptors.
Briefly, dimerized TGF-beta 1 binds to TGF-beta receptor
II (Tβ RII) and then TGF-beta receptor I (Tβ RI) complexes
[33], causing their tetramerization (two type II receptors
and two type I receptors) [34-36]. Constitutively activated
type II receptor phosphorylates and activates type I recep-
tor. Type I receptor propagates the signal by phosphorylat-
ing Smad 2, which is presented by the Smad Anchor for
Receptor Activation (SARA) [37]. Phosphorylation of
Smad destabilizes the Smad interaction with SARA, releas-
ing it [38]. On TGF-beta stimulation, Smad 2 formsBMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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heterotrimeric complexes with Smad 4 and accumulates
in the nucleus, binds DNA and remains for several hours
[39-42]. Dephosphorylation allows Smad 2 to dissociate
from Smad 4 and to be exported to the cytoplasm [43,44].
If the receptors are no longer active, then the Smads accu-
mulate over time in the cytoplasm [44]. Alternatively, acti-
vated Smad 2 is ubiquitinated in the nucleus and
undergoes proteasome-mediated degradation [45].
To create a unified model using the Gene Ontology we
have taken the biological process term, "transforming
growth factor beta (TGF-beta) receptor complex assem-
bly" (GO:0007181), and used object-oriented models to
define its dynamic and static architecture. We also show
that one can augment the biological process domain
terms by using the ontological terms and gene products
associated with this process, and integrating them into an
object-oriented model. Furthermore, we show that the
molecular function, and cellular component domains can
serve as a basis for the generation of object functions and
attributes to create a standardized, comprehensive, and
integrated model encompassing all the Gene Ontology
domains.
Results
Converting GO directed acyclic graphs to object-oriented 
diagrams
The current DAG structure in which the Gene Ontology is
represented is not readily amenable to transformation
into software code. However, the architecture of directed
acyclic graphs mimics that of an object-oriented class dia-
gram. GO terms are presented in a parent-child hierarchy
connected by 'is a' (generalizations) and 'part of' (compo-
sition) relationships. Read from top to bottom, the GO
terms proceed from more specific to less specific. Directed
acyclic graphs also allow the properties of multiple parent
Table 1: The use of object-oriented concepts in the integration of the Gene Ontology into an object-oriented model. Object-oriented 
terms, their definitions, and corresponding mechanisms of incorporating GO terms into an object-oriented model are shown. A 
specific example from the manuscript is also given. GO, Gene Ontology; DAG, directed acyclic graph; OOM, object-oriented model
Object-Oriented Term Object-Oriented Definition * Object-Oriented use of the GO Example
Class A class is a template from which 
object instances are created. It 
specifies the common 
characteristics that objects created 
from it will contain
Classes are created from gene products 
whose characteristics are defined by the 
GO molecular function and cellular 
component terms
The class Smad 2 is created based 
on the properties of the gene 
product Smad 2, which are defined 
by molecular functions such as 
"protein homodimerization' 
(GO:0042803) and 'ATP binding' 
(GO:0042301)
Object An instance of a class that contains 
unique properties
Objects are created from the template 
classes, but may contain properties 
unique to a particular object
Two different Smad 2 objects may 
be created, one of which is 
phosphorylated, and one which is 
not
Inheritance Relationships between classes, 
whereby a more specific class 
inherits all the properties and 
methods of the classes they belong 
to
Relationships defined by 'is a' are 
generalizations in which child classes of 
the DAG inherit the properties of the 
parent class (if a child class has multiple 
parent classes, multiple inheritance 
applies)
The cellular component 'plasma 
membrane' (GO:0005886) inherits 
the properties of the general class 
cellular component 'membrane' 
(GO:0016020)
Composition Certain objects may be assembled 
from collections of other objects
'part_of' relationships defined in the GO 
DAG are rendered as composition 
relationships in an OOM
The 'membrane' (GO:0005623) 
and 'intracellular' (GO:0005622) 
space are part of the 'cell' 
(GO:0005623)
Polymorphism The ability of an object to 
interpret messages differently 
when received by different objects
GO functions may change for different 
proteins and be given different input and 
output values
The function 'protein 
homodimerization activity' 
(GO:0042803) in the context of 
SMAD2 accepts two SMAD2s and 
outputs a dimerized SMAD2, 
whereas in the context of TGF-
beta receptor II it accepts two 
receptors and outputs a dimerized 
receptor
Encapsulation Hiding the state and 
implementation of an object
The exact mechanism by which an 
object is created is hidden in an OOM
The details involved in the 
translation (GO: 0043037) of 
Smad 2 are hidden, but a Smad 2 
molecule is still created
*[53]BMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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nodes to be inherited by child nodes, a form of multiple
inheritance in object-oriented modeling. In figure 1A, cel-
lular components related to the TGF-beta receptor com-
plex are shown. One can create a UML diagram to mimic
these relationships as shown in figure 1B. Since not all cel-
lular components involved in the TGF-beta receptor com-
plex assembly process are present in the current Gene
Ontology, additional gene products based on literature
searches were added to the object-oriented diagram (Fig-
ure 1B, shaded boxes). Relationships are captured as an
object-oriented system through containment, composi-
tion and inheritance. Cellular components were decom-
posed into objects and connected via generalizations,
which illustrate inheritance. Because these terms inherit
all the attributes of their parents, only GO terms at the ter-
minal nodes need be characterized in an object-oriented
model. Relationships described as 'part of' were also
extrapolated into object-oriented terms as composition.
The functions of gene products were also decomposed
into object functions. The creation of object functions
involved the transition from gene product functions to
standardized GO molecular functions, and then to stand-
ardized, fully parameterized object functions. By applying
formal ontological terms from the molecular function
domain to gene products, object functions can be created
with a consistent vocabulary. In table 2 we show the rela-
tionships between the function of a gene product defined
in our model, and the GO molecular function term most
closely corresponding to that cellular function. Here, we
first compared ontology terms from the molecular func-
tion domain to those ascribed to individual gene prod-
ucts. Due to the incompleteness of the Gene Ontology,
some gene product functions were extrapolated from the
current literature, and then comparable GO molecular
function terms were assigned to the gene products. Next,
these molecular function terms were converted to object
functions through reverse engineering. We identified the
The GO terms associated with the process, TGF-beta receptor complex assembly (GO: GO:0007181) Figure 1
The GO terms associated with the process, TGF-beta receptor complex assembly (GO: GO:0007181). Lines 
with solid diamonds ( ) at the end indicate composition. These are read from the diamond end, for example, as 'cell' 
(GO:0005623) contains a 'membrane' (GO:0016020). Lines with open triangles ( ) represent generalizations. These are 
read from the triangle end, as a 'membrane' (GO:0016020) is a general type of 'plasma membrane' (GO:0005886). A) Directed 
acyclic graph for the cellular component GO terms associated with TGF-beta receptor complex assembly (GO:0007181). B) 
Object-oriented representation of the DAG described in Figure 1A (white). Additional cellular components not represented 
by the current Gene Ontology, but essential to the TGF-beta receptor complex assembly process are shown in the gray boxes 
(i.e. TGF-beta, TGF-beta receptors, SMAD2)BMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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parameters that would normally be input into and output
from a cellular reaction. In this way we defined the input
and output parameters necessary for an object function.
The object function itself was given the GOid that corre-
sponds with its closest matching molecular function as
defined by the GOid's definition. Together, object func-
tions were created that are fully parameterized with inputs
and outputs and that contain a standardized GO notation.
We conclude that it is feasible to create standardized func-
tions for objects based on the current literature and an
approved ontology. Together, ontological terms can be
integrated into an object-oriented model paralleling the
relationships, capturing the inherited aspects of the GO
terminology, and providing a compact architecture while
maintaining a standardized notation.
Sequence diagram generation
The GO biological process term, TGF-beta receptor com-
plex assembly (GO:0007181), contains both static and
dynamic features. The events of the TGF-beta receptor
complex assembly (GO:0007181) process include TGF-
beta binding (GO:0050431) to its receptors and SMAD
binding (GO:0046332) and activation (GO:0042301). To
capture the dynamic nature of these actions as an object-
oriented software system, sequence diagrams were cre-
ated. The events leading to Smad 2 activation are reflected
chronologically in a high-level sequence diagram in Fig-
ure 2. The creation of the sequence diagram first entails
identifying gene products and their functions by literature
searches. Simple or complex bioentities are modeled as
objects, which are represented by rectangles with vertical
lifelines. Ontology terms taken from the molecular func-
tion domain that best corresponded to these functions
Table 2: The gene product functions described herein are listed with their associated GO molecular functions and parameters. These 
gene product functions are mapped to corresponding Gene Ontology molecular functions. These GO functions are integrated into an 
object-oriented model by amending them with input and output parameters, thereby creating object functions.
Gene Product Gene Product 
Function
Corresponding GO Term and 
GO ID
Input Output Figure 
Location
TGF-beta Dimerize protein homodimerization activity 
(GO:0042803)
2X TGF-beta Dimerized TGFβ Fig.4
bind TGF-beta 
receptor
TGF-beta receptor binding 
(GO:0005160)
TGFβ  homodimer
TGFβ R homodimer
TGFβ -TGFβ R complex Fig.4
Tβ RII Dimerize protein homodimerization activity 
(GO:0042803)
2X Tβ RII Dimerized RII Fig.4
TGF-beta binding TGF-beta binding (GO:0060431) Tβ RII homodimer
TGFβ  homodimer
TGFβ -Tβ RII 
heterotetramer
Fig.2, 4
Heterotetramerize protein heterodimerization activity 
(GO:0046982)
Tβ RI homodimer
Tβ RII homodimer
Tβ RI-Tβ RII 
heterotetramer
Fig.2, 4
phosphorylate RI transferase activity (GO:0016740) ATP
Tβ RI homodimer
phosphorylated Tβ RI Fig.2, 4
Tβ RI Dimerize protein homodimerization activity 
(GO:0042803)
2X Tβ RI Dimerized RI Fig.4
Heterotetramerize protein heterodimerization activity 
(GO:0046982)
Tβ RI homodimer
Tβ RII homodimer
Tβ RI-Tβ RII heterodimer Fig.2, 4
Tβ RI activation phosphate binding (GO:0042301) ATP
Tβ RI
phosphorylated Tβ RI Fig.4
bind SMAD2 Smad binding (GO:0046332) SMAD2 TGFβ -Tβ RII-Tβ RI-
SMAD2 complex
Fig.2, 4
phosphorylate Smad transferase activity (GO:0016740) ATP
SMAD2
phosphorylated SMAD2 Fig.2, 4
SMAD2 bind Tβ RI TGF-beta receptor binding 
(GO:0005160)
TGFβ  homodimer
Tβ RI homodimer
TGFβ -Tβ RII-Tβ RI-
SMAD2 complex
Fig.4
SMAD2 activation phosphate binding (GO:0042301) ATP
SMAD2
phosphorylated SMAD2 Fig.4
Trimerize protein heterodimerization activity 
(GO:0042803)
SMAD2
SMAD2 homodimer
Trimerized SMAD2 Fig.4
activate transcription DNA binding (GO:0003677) DNA
SMAD2
SMAD2-DNA complex Fig.4BMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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were incorporated as object functions, which represent
the functions of these gene products. These functions are
implemented by the methods contained within the
objects. Furthermore, these methods allow an object to
communicate and interact with other objects, thus captur-
ing cellular activities. To capture interactions between
objects, one object can call a method of another object by
connecting object lifelines in the sequence diagram (Fig-
ure 2). This invocation of a function of one object by
another is described as one object sending a message to
another object. Alternatively, a message may be passed
from an object to itself as in the case of self-checks or
autoactivation signals. In this way, real world processes
may be captured using an object-oriented approach. For
instance, to capture the formation of the TGF-beta and
TGF-beta RII complex a GOid that closely corresponds to
this ability is chosen as the method name. In this way the
method can be cross-referenced to a GO term. Specifically,
the method 'GO:0046982 (in Dimerized_TGF-beta, in
Dimerized_RII)' references via the GOid, GO:0046982,
"protein heterodimerization activity", and shows that a
homodimer of TGF-beta and a homodimer of TGF-beta
RII are needed to form the complex. Here, each dimer is
thought of as a single entity, so the combination of these
two entities is best represented as heterodimerization. A
value of TGF-beta-Tβ RII_Complex is returned upon com-
pletion of the method as indicated by the return arrow. In
contrast, the function call "GO:0042803 (in: SMAD2, in
SMAD2)," references a self-call. The GOid can be cross-
referenced to "protein homodimerization activity", which
requires two SMAD2 components to generate the SMAD2
homodimer, but the message is passed only within the
SMAD2 object. Furthermore, a message need not accept
any parameters, as in the "translate()" function, which
only returns a Boolean value indicating whether the
action has occurred. Additional events such as TGF-beta
RI activation, and Smad homodimerization, binding and
activation are also reflected in figure 2. Together, this dia-
gram demonstrates that the sequence of events occurring
in the biological process, TGF-beta receptor complex
assembly (GO:0007181), can be represented using the
Gene Ontology, and can be integrated as part of the
dynamics of an object-oriented software system.
Activity diagram generation
Biological processes are created from a series of complex
events. While there may be one main event scenario that
most frequently leads to a specific outcome often, alterna-
tive scenarios that lead to a process conclusion exist. This
is exemplified by the sequence of events found in the TGF-
beta receptor complex assembly (GO:0007181). For
instance, TGF-beta may initially bind to TGF-beta RII or
TGF-beta RIII. To capture these alternative events as part
of the dynamic architecture, an activity diagram was cre-
An example of the sequence diagram showing the TGF-beta receptor complex assembly (GO:0007181) Figure 2
An example of the sequence diagram showing the TGF-beta receptor complex assembly (GO:0007181). The 
binding of TGF-beta to its receptor (GO:0050431), receptor heterotetramerization (RI and RII homodimers, heterodimeriz-
ing)(GO:0046982), translation (GO:0043037), transferase activity (GO:0016740), and Smad 2 binding (GO:0046332) and acti-
vation (GO:0042301) are shown.BMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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ated to reflect the initial stages of TGF-beta signaling (Fig-
ure 3). Unlike the sequence diagram, which captures main
scenario events, the action sequence or flow of the activity
diagram can portray alternative outcomes. Taking the
example above, if TGF-beta binds to the type III receptor
then an alternative flow of events occurs for a time that
then returns to the main flow of events. Other possible
divergences that were modeled included whether to inter-
nalize the TGF-beta receptors via clathrin-dependent or
lipid raft-dependent mechanisms. These pathways lead to
either complex degradation or signal promotion. Because
complex degradation is not specified in our use case, for
simplicity, this event is routed to the final state. However,
the main success scenario, signal promotion, continues
until SMAD2 is released and TGF-beta complex assembly
is finished. Together, the dynamic events occurring during
the biological process, TGF-beta receptor complex assem-
bly (GO:0007181) are captured.
Class diagram generation
The major components of a biological system are bioenti-
ties with functions and interactions. Likewise, the center
of an object-oriented software system is objects. Complex
bioentities formed from multiple gene products along
with their relationships, are contained within the biologi-
cal system encompassing the biological process term,
TGF-beta receptor complex assembly (GO:0007181). To
represent the components that execute the process, we
captured these components as bioentities with functions,
and their interactions. The events of the TGF-beta receptor
complex assembly (GO:0007181) process include TGF-
beta binding (GO:0050431) to its receptors, and SMAD
binding (GO:0046332) and activation (GO:0042301). To
capture this static architecture, class diagrams were gener-
ated that model the bioentities, operations, and
interrelationships that occur between TGF-beta, its recep-
tors, and Smad 2. Similarly to figure 1, figure 4 captures
the major components of the initial phases of TGF-beta
signaling as objects with their associations, using an
object-oriented representation. However, unlike figure 1,
this object-oriented representation of the components of
the main receptor complex is enhanced by the addition of
attributes and functions. These objects were given
attributes that describe important characteristics that if
changed, might alter the function of a component. The
functions of the objects, which parallel gene product func-
tions, were generated from the sequence diagrams and
were represented using Gene Ontology terms. These func-
tions or operations are a declaration of the methods that
an object may use. Together, the models generated using
the described object-oriented methodology yield a soft-
ware system representation of a biological process, TGF-
beta receptor complex assembly, capturing both static and
dynamic relationships annotated with Gene Ontology
terms.
In addition, the UML notation provides a mechanism to
specify inheritance that may be used to indicate an object
that is the foundation for other objects. For instance, a
TGF-beta receptor object might be a generalization of the
TGF-beta receptor I object (data not shown). These spe-
cific objects inherit the properties of the receptor object.
In addition, binary associations containing cardinalities
may indicate the number of objects interacting with
another. For instance, TGF-beta can interact with one to
many receptors, while a receptor can only interact with
one TGF-beta at a time (Fig. 4). Cellular compartments
where these gene products can be found are also shown.
Here, guard conditions are added to distinguish condi-
tions under which each gene product might be found in a
particular cellular compartment. In this way, a spatial rep-
resentation of the TGF-beta receptor complex
components is also achieved. These class diagrams dem-
onstrate that the static structure of a biological system can
be represented as an object-oriented model with inte-
grated Gene Ontology terms. Collectively, the models
generated using the described object-oriented methodol-
ogy yield a software system representation of a biological
system, capturing both static and dynamic relationships
annotated with integrated Gene Ontology terms.
Discussion
We have utilized the Gene Ontology to construct an
object-oriented representation of the initial steps of TGF-
beta signaling, and the gene products contained therein.
In doing so, we have provided a standardized framework
for the integration of Gene Ontology terms into gene
product descriptions. By capturing all of the relevant GO
terms in one model, the disjointed GO vocabulary is
assembled into a cohesive structure. This cohesive struc-
ture encompasses the fundamental concepts of the object-
oriented paradigm.
We proposed a solution to three unaddressed issues
within the current Gene Ontology. First, while the Gene
Ontology has helped to formalize the vocabulary that
describes biological systems, it lacks a specific integration
method. Currently, when applied to gene products, Gene
Ontology terms are only categorically listed. Second, the
Gene Ontology domains, biological process, molecular
function and cellular component lack coherence. In par-
ticular, no association exists between domains. Finally,
the current Gene Ontology defines GO terms, but gives no
indication of what is necessary to accomplish a particular
function, or process. To resolve these problems we
defined an object-oriented methodology and architecture
that provides a unifying framework to integrate all Gene
Ontology domains.
The central dogma of the object-oriented paradigm
revolves around several key aspects. Specifically, anBMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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An example of an activity diagram showing the main and alternative flow of events occurring during TGF-beta receptor com- plex assembly (GO:0007181) Figure 3
An example of an activity diagram showing the main and alternative flow of events occurring during TGF-beta receptor com-
plex assembly (GO:0007181).BMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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object-oriented framework should accommodate the
class, object, inheritance, composition, encapsulation and
polymorphism concepts. As shown in table 1, gene prod-
ucts and other bioentities can be decomposed into
objects, which are created based on template classes.
These objects utilize inheritance to acquire the attributes
and properties of more general objects. Complex classes
can also be disassembled into subclasses using composi-
An example of a class diagram showing the interactions between the components of the TGF-beta receptor complex  (GO:0007181) (grayed) Figure 4
An example of a class diagram showing the interactions between the components of the TGF-beta receptor 
complex (GO:0007181) (grayed). Cellular components containing these gene products are also shown. Due to space con-
straints functions are named using their corresponding GO ids. The class diagram was also constructed with a descriptive func-
tion name [see Additional file 8]. The GOid reference list is: GO:0042803, protein homodimerization activity; GO:0005160, 
TGF beta receptor binding; GO:0046982, protein heterodimerization activity, GO:0050431, TGF beta binding, GO:0005524, 
ATP binding; GO:0016740, transferase activity, GO:0046332, Smad binding; GO:0042301, phosphate binding; GO:0003677, 
DNA binding.BMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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tion. Encapsulation allows the simplification of the
model without sacrificing functionality. For instance, we
do not need to know specific details regarding how a gene
product is translated, just that a process that is encapsu-
lated by the function 'translate()' can create a protein.
However, if we wished to delve deeper into the mechanics
of the translation process the layered architecture of the
object-oriented system would allow us to do so. It is also
worth noting that the modular nature of the object-ori-
ented system closely resembles the recently discovered
modular structure of biological networks [46-48]. This
resemblance further indicates that biological systems can
be easily modeled as object-oriented systems. Finally,
polymorphism allows one to describe shared functions
among different gene products. In this way, a function
that may be shared broadly with other gene products can
be uniquely specified for a particular gene product.
By applying object-oriented methodologies and concepts
the various domains of the Gene Ontology can be coordi-
nated into one model. Currently, the mechanisms in the
biological process domain are veiled. There is no
indication as to what gene products form the biological
process, or what molecular functions are necessary to
accomplish the process. Furthermore, the outcome of a
specific process is not obvious. As in our example, a proc-
ess such as TGF-beta receptor complex assembly
(GO:0007181) does not give any indication of the com-
ponents, dynamics or outcomes that occur during this
process. However, by incorporating GO terms as
attributes and functions we can discern relationships
between the three domains. Likewise, the cellular compo-
nents domain does not provide temporal or spatial clues
when applied to gene products. For instance, GO terms
'extracellular' and 'intracellular' may both be associated
with a particular gene product. However, the distinction
between when a gene product is extracellular and when it
is intracellular is not apparent. By applying object-ori-
ented principles we can set extracellular and intracellular
to Boolean values, and we can specify which location is
the current (true) location of a gene product.
In addition, by using object-oriented principles a GO
molecular function term can be augmented with parame-
ters and outcomes. For example, the function
"GO:0046982: protein heterodimerization activity" has
different input and output parameters depending on the
particular protein that contains the function. This type of
polymorphic behavior, where one function can be per-
formed in multiple ways is not supported by the Gene
Ontology. For example, protein A may heterodimerize
with protein B, whereas protein C heterodimerizes with
protein D. From the Gene Ontology it is not readily
apparent as to what is being inputted into the dimeriza-
tion function. However, by applying an object-oriented
architecture to function "GO:0046982: protein het-
erodimerization activity" we get "GO:0046982 (in: Pro-
tein A, in: Protein B): Protein AB". This format is an
improvement to the unparameterized GO term in that the
function can be cross-referenced to protein heterodimeri-
zation activity via its GO term, and we also see that for
protein A to heterodimerize we need both protein A and
protein B. In addition, we now observe that a new entity
called protein AB is created from this function. By captur-
ing the above details in an object-oriented model the GO
term becomes far more useful for both biologists and
computer scientists. Using an object-oriented approach
the Gene Ontology domains are integrated into one cohe-
sive model.
Integration of the Gene Ontology terms into an object-ori-
ented representation offers several additional benefits.
The object-oriented model provides additional levels of
detail not found in the Gene Ontology. One of the
strengths of object-oriented technology is the ability to
capture the dynamics of a system. For example, sequence
diagrams can chronologically order events in a biological
process. Activity diagrams afford one the opportunity to
envision different scenarios that might be occurring in a
process. This additional level of detail significantly
increases the depth of information that can be applied to
the description of a biological process. State-transition
diagrams also contribute to the realization of the full
dynamics of a process by allowing the visualization of
gene product states within a process. Furthermore, UML
models can be translated into code, facilitating the crea-
tion of simulations.
The standardization of biological system modeling and
integration is growing rapidly. A widely accepted example
of the drive toward standardization is the Systems Biology
Markup Language (SBML) [49], which has been adopted
by more than 70 software tools [50]. The Gene Ontology
is another example. However, each of the technologies,
the Gene Ontology, the object-oriented approach, and
SBML, has strengths and weaknesses. The Gene Ontology
provides a standardized vocabulary but contains discon-
nected domains with no details regarding terms. SBML
was developed to communicate biological models, with
an emphasis on mathematical modeling of biological
systems, but does not specify how to construct these mod-
els. Object-oriented technologies, on the other hand, pro-
vide a well-defined process for model creation and
visualization, but have not been standardized for biology.
However, the Gene Ontology, object-oriented paradigm,
and SBML can form a new synergism when jointly applied
to a common biological system model. These technolo-
gies are steps toward a unified approach to biological
information integration, and studying biological phe-
nomena at the systems level. Together, this unifiedBMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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approach will make biological system integration and
analysis consistent, manageable and controllable, which
is essential in handling complex systems, as demonstrated
by decades of software industry experience.
While the described object-oriented approach can signifi-
cantly enhance the annotation of gene products using the
Gene Ontology, several challenges will need to be
addressed. Specifically, object-orientation was not specifi-
cally designed for use in biological systems. Therefore, its
use in capturing biological systems is not well defined.
Furthermore, the Gene Ontology is still expanding and
undergoing revisions. Consequently, in the near future it
will still be necessary to do literature searches to define all
the gene ontologies associated with a gene product. How-
ever, automated extraction of information for UML model
generation and software implementation for simulations
is under development, but is beyond the scope of this
paper.
Future systems may also be implemented as software
libraries in object-oriented programming languages (C++
and Java) for computer scientists to construct software for
various applications and can be distributed as part of the
GO-DEV toolkit for Gene Ontology development [29]. In
addition, reformatting gene products with Gene Ontology
terms will require the cooperation of multiple groups of
biologists and computer scientists. However, we must
take into consideration that a primary issue with this
approach is the lack of people with cross-disciplinary
skills able to comprehend both the biology and the com-
puter science. Nonetheless, our own experience has
shown that with supervision one biologist without a for-
mal computer science background can learn to model a
biological system using UML in a matter of months. Fur-
thermore, automation of some of the annotation process
will significantly reduce the human effort, but not elimi-
nate the need for human annotators. Additional standards
for automation will also need to be developed to thor-
oughly specify the process of object-oriented biological
system integration. Despite these challenges the ultimate
goal of creating a library of UML objects or modules inte-
grated with Gene Ontology attributes and functions is
worthwhile. Through this endeavor, biological processes
could be assembled from these libraries for the develop-
ment of simulation tools that will increase the productiv-
ity of biologists through increased insight into disease
pathways and mechanisms.
Conclusion
Here, we have demonstrated that Gene Ontology terms
can be integrated into an object-oriented model. Further-
more, the object-oriented technology and methodologies
used for this integration should improve the usability of
these terms, and increase the depth of information that
they contain. This work also serves as a framework for
reverse-engineering biological gene products as objects in
an object-oriented system. Together, this should facilitate
additional collaborations between biologists and compu-
ter scientists.
Methods
UML representations of the TGF-beta receptor complex
assembly process were created following a software engi-
neering process consisting of phases of requirement-gath-
ering, analysis and design. UML models were generated
using Microsoft Visio Pro. AmiGO [51] was used to deter-
mine Gene Ontology links for TGF-beta gene products.
Requirement-gathering phase
Information collection
To define the requirements and collect the information
necessary for the generation of the models, two
approaches were necessary. First, annotations of the TGF-
beta signaling pathways were conducted during an
extensive literature review. Second, gene ontologies and
Uniprot entries were searched to assign Gene Ontology
terms to gene products. The attributes and the interactions
of the TGF-beta signaling components were captured
using class-responsibility collaboration (CRC) cards as
described previously [52] [see Additional files 1, 2, 3, 4].
Use case development
Based on the gathered information, best-case and alterna-
tive scenarios were developed within a so-called "use
case" to describe the TGF-beta receptor complex assembly
process [see Additional file 5]. The use case also serves to
define the boundary and scope of the TGF-beta model.
For demonstration purposes the boundary of the system
was limited to the steps TGF-beta receptor complex assem-
bly. Therefore, alternative events such as receptor ubiqui-
tination and degradation, as well as the specifics of SMAD
2 mobility were not captured in the dynamic models (i.e.
sequence diagram).
Analysis phase
Conceptual model generation
To provide an overview of the system and its interrelation-
ships a conceptual based on the information defined in
the requirement-gathering phase was generated [see Addi-
tional file 6]. This conceptual model integrated biological
information, and represented TGF-beta and the cellular
components involved in the complex assembly and their
relationships in UML notation. By applying object-ori-
ented analysis, the TGF-beta receptor complex assembly
was decomposed into objects and component relation-
ships were realized. However, information regarding
component properties is hidden through encapsulation.
This conceptual model defines the organization of theBMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
Page 12 of 14
(page number not for citation purposes)
biological system and provides an overview of the compo-
nents and their relationships.
Design phase
State diagram generation
The dynamics of the system can also be captured using
state diagrams, which can be used to describe the transi-
tions and different states that a cellular component can
exist [see Additional file 7]. In addition, multiple concur-
rent states can be illustrated using this UML notation.
Sequence, activity, class diagram generation
Sequence, activity and class diagrams have been used as
an example to demonstrate the feasibility of generating an
object-oriented representation of the biological process
described by the GO term TGF-beta receptor complex
assembly (GO:0007181), with Gene Ontology terms
applied to generate these diagrams. Objects representing
corresponding gene products are created, and their essen-
tial attributes are captured. Interactions among objects are
also identified. For each interaction, a corresponding
method is generated. This method is matched to a Gene
Ontology term. The nature of the interaction determines
the method parameters. The sequence of events is cap-
tured, and used to generate sequence diagrams. Scenarios
are also generated for object interactions, and used to gen-
erate activity diagrams. The information captured in the
sequence diagram and activity diagrams are used, along
with the gene products attributes, to generate class
diagrams.
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Additional material
Additional File 1
Class-responsibility-collaboration card for TGF-beta 1. Attributes, col-
laborators and responsibilities of the specified protein are given. The 
attributes section allows the ordered listing of information not easily cap-
tured by the UML notation. The collaborator section lists the cellular com-
ponents that interact with TGF-beta 1. The responsibilities section 
specifies the consequence of TGF-beta 1 interacting with its collaborator. 
This card allows TGF-beta 1 to be decomposed into an object containing 
attributes, operations and interactions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-6-113-S1.pdf]
Additional File 2
Class-responsibility-collaboration card for TGF-beta receptor II. 
Attributes, collaborators and responsibilities of the specified protein are 
given. The attributes section allows the ordered listing of information not 
easily captured by the UML notation. The collaborator section lists the cel-
lular components that interact with TGF-beta receptor II. The responsibil-
ities section specifies the consequence of TGF-beta receptor II interacting 
with its collaborator. This card allows TGF-beta receptor II to be decom-
posed into an object containing attributes, operations and interactions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-6-113-S2.pdf]
Additional File 3
Class-responsibility-collaboration card for TGF-beta receptor I. 
Attributes, collaborators and responsibilities of the specified protein are 
given. The attributes section allows the ordered listing of information not 
easily captured by the UML notation. The collaborator section lists the cel-
lular components that interact with TGF-beta receptor I. The responsibil-
ities section specifies the consequence of TGF-beta receptor I interacting 
with its collaborator. This card allows TGF-beta receptor I to be decom-
posed into an object containing attributes, operations and interactions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-6-113-S3.pdf]
Additional File 4
Class-responsibility-collaboration card for SMAD2. Attributes, collab-
orators and responsibilities of the specified protein are given. The 
attributes section allows the ordered listing of information not easily cap-
tured by the UML notation. The collaborator section lists the cellular com-
ponents that interact with SMAD2. The responsibilities section specifies 
the consequence of SMAD2 interacting with its collaborator. This card 
allows SMAD2 to be decomposed into an object containing attributes, 
operations and interactions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-6-113-S4.pdf]
Additional File 5
Use case describing the events leading to TGF-beta receptor complex 
assembly. This use case defines the boundaries of the system model. Here, 
the main success and alternative scenarios leading to the assembly of the 
TGF-beta receptor complex are described.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-6-113-S5.pdf]
Additional File 6
Conceptual diagram of the TGF-beta receptor complex, and the pro-
teins that associate with this complex. Gene products have been decom-
posed into objects. Object attributes and operations are hidden to reduce 
complexity. Gene products that comprise the receptor complex are shown 
in blue with their associated relationships in green. As the boundaries of 
the use case do not include them, other associated proteins that comprise 
the TGF-beta signaling pathway are not emphasized in further diagrams.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-6-113-S6.pdf]BMC Bioinformatics 2005, 6:113 http://www.biomedcentral.com/1471-2105/6/113
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